Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026)

Denali Therapeutics has reported Income from Continuing Operations over the past 9 years, most recently at 128447000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 12.0% to 128447000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 512438000.0 through Dec 2025, down 21.23% year-over-year, with the annual reading at 512540000.0 for FY2025, 21.23% down from the prior year.
  • Income from Continuing Operations was 128447000.0 for Q4 2025 at Denali Therapeutics, down from 126902000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 183383000.0 in Q2 2023 and troughed at 132970000.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 100577500.0 (2023), against an average of 84910850.0.
  • Year-over-year, Income from Continuing Operations skyrocketed 411.91% in 2023 and then tumbled 154.0% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 75261000.0 in 2021, then plummeted by 31.11% to 98678000.0 in 2022, then fell by 21.07% to 119473000.0 in 2023, then rose by 4.01% to 114685000.0 in 2024, then fell by 12.0% to 128447000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Income from Continuing Operations are 128447000.0 (Q4 2025), 126902000.0 (Q3 2025), and 124119000.0 (Q2 2025).